CMS sickle cell disease action plan
FDA-approved gene therapies for sickle cell disease
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease The Medical Letter
Exagamglogene autotemcel
- Exagamglogene autotemcel MedlinePlus, National Library of Medicine
- CASGEVY – exagamglogene autotemcel injection, suspension DailyMed, National Library of Medicine
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
- Casgevy FDA
Lovotibeglogene autotemcel
- Lovotibeglogene autotemcel Injection MedlinePlus, National Library of Medicine
- LYFGENIA – lovotibeglogene autotemcel suspension DaliyMed, National Library of Medicine
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
- Lyfgenia FDA
-
FDA-approved gene therapies for sickle cell disease
Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease The Medical Letter
Exagamglogene autotemcel- Exagamglogene autotemcel MedlinePlus, National Library of Medicine
- CASGEVY – exagamglogene autotemcel injection, suspension DailyMed, National Library of Medicine
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
- Casgevy FDA
Lovotibeglogene autotemcel- Lovotibeglogene autotemcel Injection MedlinePlus, National Library of Medicine
- LYFGENIA – lovotibeglogene autotemcel suspension DaliyMed, National Library of Medicine
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
- Lyfgenia FDA
Clinical trials
Learn About Studies ClinicalTrials.gov
-
Clinical trials
Learn About Studies ClinicalTrials.gov
The Democratizing Education Project welcomes your feedback about the sickle cell disease gene therapy resources. Please email your comments or questions to DemocratizingEd@mail.nih.gov.
These educational materials are for informational purposes only. They are meant to promote your general understanding of gene therapy for sickle cell disease. We encourage you to use these educational materials to talk with your healthcare provider or a clinical trial team.
Last updated: September 27, 2024